NuVasive, Inc. (NUVA) - NASDAQ
  • Fri, Jul. 15, 7:16 AM
    • Mead Johnson Nutrition (NYSE:MJN) upgraded to Neutral from Underperform with a $96 (5% upside) price target by Bank of America.
    • NuVasive (NASDAQ:NUVA) upgraded to Overweight from Neutral by JPMorgan. Price target raised to $74 (21% upside) from $55.
    • Wright Medical Group (NASDAQ:WMGI) upgraded to Overweight from Neutral by JPMorgan. Price target raised to $26 (21% upside) from $21.
    • Horizon Pharma (NASDAQ:HZNP) upgraded to Equal Weight from Underweight with a $24 (28% upside) price target by Morgan Stanley.
    • Alexion Pharmaceuticals (NASDAQ:ALXN) upgraded to Outperform from Neutral by Credit Suisse. Price target lowered to $165 (32% upside) from $185.
    • HeartWare International (NASDAQ:HTWR) downgraded to Market Perform from Outperform with a $58 (1% upside) price target by Leerink Swann.
    | Fri, Jul. 15, 7:16 AM | 2 Comments
  • Fri, May 27, 4:56 PM
    • Globus Medical (NYSE:GMED) initiated with Equal Weight Rating and $26 (8% upside) price target by Barclays.
    • TG Therapeutics (NASDAQ:TGTX) initiated with Buy rating $18 (133% upside) price target by SunTrust Robinson Humphrey.
    • Karyopharm Therapeutics (NASDAQ:KPTI) initiated with Outperform rating and $13 (35% upside) price target by Raymond James.
    • SAGE Therapeutics (NASDAQ:SAGE) initiated with Sell rating and $18 (43% downside risk) price target by Chardan Capital.
    • Viking Therapeutics (NASDAQ:VKTX) initiated with Buy rating with a $5 (285% upside) price target by Maxim Group.
    • Fibrocell Science (NASDAQ:FCSC) resumed with Buy rating and $7 (229% upside) price target by Roth Capital Partners.
    • Asterias Biotherapeutics (NYSEMKT:AST) initiated with Buy rating and $5.50 (61% upside) price target by Chardan Capital.
    • Quorum Health (NYSE:QHC) initiated with Market Perform rating and $14 (6% upside) price target by Avondale Partners.
    • Radius Health (NASDAQ:RDUS) initiated with Buy rating and $55 (57% upside) price target by H.C. Wainwright.
    • Johnson & Johnson (NYSE:JNJ) initiated with Sell rating and $94 (17% downside risk) price target by Standpoint Research.
    • NuVasive (NASDAQ:NUVA) upgraded to Overweight from Equal Weight by Barclays. Price target raised to $63 (15% upside) from $58.
    • Zimmer Biomet Holdings (NYSE:ZBH) upgraded to Buy from Hold with a $125 (2% upside) price target by Argus Research.
    • Relypsa (NASDAQ:RLYP) upgraded to Equal Weight from Underweight with a $9 (50% downside risk) price target by Morgan Stanley. To be adjusted after ZS-9 rejection.
    • Ionis Pharmaceuticals (NASDAQ:IONS) downgraded to Market Perform from Outperform by BMO Capital Markets. Price target lowered to $26 (18% upside) from $55.
    • Patterson Companies (NASDAQ:PDCO) downgraded to Hold from Buy by Evercore ISI. Price target lowered to $48.50 (0% upside) from $49.50.
    • United Therapeutics (NASDAQ:UTHR) downgraded to Sell from Hold with a $114 (3% downside risk) price target by Argus Research.
    • Boston Scientific (NYSE:BSX) downgraded to Neutral from Buy with a $24.20 (7% upside) price target by BTIG Research.
    • Neovasc (NASDAQ:NVCN) downgraded to Neutral from Buy by Ladenburg Thalmann. Price target removed.
    | Fri, May 27, 4:56 PM | 17 Comments
  • Tue, Apr. 26, 4:53 PM
    • NuVasive (NASDAQ:NUVA) Q1 results ($M): Total Revenues: 215.1 (+11.8%); Operating Expenses: 148.6 (+62.9%); Net Loss: (8.9) (-128.2%); Loss Per Share: (0.18) (-129.5%); Non-GAAP EPS: 0.31 (+3.3%); CF Ops: 57.4 (+120.8%).
    • 2016 Guidance: Revenues: ~$928M; EPS: 0.20 from 1.02; Non-GAAPEPS:~$1.48.
    • Shares are up 3% after hours on light volume.
    | Tue, Apr. 26, 4:53 PM
  • Tue, Apr. 26, 4:26 PM
    • NuVasive (NASDAQ:NUVA): Q1 EPS of $0.31 beats by $0.04.
    • Revenue of $215M (+11.8% Y/Y) beats by $9.33M.
    • Press Release
    | Tue, Apr. 26, 4:26 PM
  • Mon, Apr. 25, 5:35 PM
  • Fri, Feb. 12, 8:47 AM
    • NuVasive (NUVA) Q4 results: Revenues: $215.3M (+5.4%); R&D Expense: $8.6M (-8.5%); SG&A: $121.7M (+0.7%); Net Income: $11.5M (+53.3%); EPS: $0.22 (+46.7%); Non-GAAP EPS: $0.35 (+34.6%).
    • FY2015 results: Revenues: $811.1M (+6.4%); R&D Expense: $35.9M (-5.5%); SG&A: $464.5M (-0.8%); Net Income: $66.3M (+497.0%); EPS: $1.26 (+450.0%); Non-GAAP EPS: $1.31 (+95.5%); Quick Assets: $357.8M (-1.4%).
    • 2016 Guidance: Revenue: ~$923M; GAAP EPS: ~$1.02; Non-GAAP EPS: ~$1.48.
    | Fri, Feb. 12, 8:47 AM
  • Thu, Feb. 11, 4:12 PM
    • NuVasive (NASDAQ:NUVA): Q4 EPS of $0.35 beats by $0.04.
    • Revenue of $215.3M (+5.4% Y/Y) in-line.
    • Shares -0.6%.
    • Press Release
    | Thu, Feb. 11, 4:12 PM
  • Wed, Feb. 10, 5:35 PM
  • Tue, Jan. 12, 8:07 AM
    • On a preliminary basis, NuVasive (NASDAQ:NUVA) expects total revenue for Q4 and full-year 2015 to be ~$215M (+5%) and ~$811M (+6%), respectively. Non-GAAP operating margin should exceed guidance of 15.2%.
    • For 2016, revenues are expected to be $870M (+7%). The Ellipse Technologies acquisition should add $0.01 to EPS this year and $0.18 in 2017.
    • Final results and more detailed guidance will be announced in mid-February.
    | Tue, Jan. 12, 8:07 AM
  • Tue, Jan. 5, 4:36 PM
    • NuVasive (NASDAQ:NUVA) acquires privately held Ellipse Technologies for $380M cash upfront and a potential $30M milestone payable in 2017 related to specific revenue targets. NUVA expects the transaction to accelerate its top line growth in the high-single-digit range and be slightly accretive to its non-GAAP EPS in the first year and significantly accretive thereafter.
    • Ellipse develops devices used in orthopedic surgery. Its PRECICE device is an intramedullary nail used to lengthen the femur and tibia and MAGEC is a spinal bracing and distraction system.
    • NuVasive will host a conference call today at 5:00 pm ET to discuss the deal.
    | Tue, Jan. 5, 4:36 PM
  • Dec. 10, 2015, 11:11 AM
    • NuVasive (NUVA +1.3%) hosts its Investor Day today in San Diego during which it will present its long-term goals to drive growth and margin expansion. The goals include:
    • Constant currency organic revenue growth of mid-to-high single digit with a near doubling of the revenue contribution from international operations.
    • Non-GAAP operating profit expansion of ~10% to ~25%.
    • Non-GAAP EBITDA margin expansion of ~6.6% to ~32%.
    • Reduction of effective tax rate to ~30% from today's ~43%.
    • Expanding free cash flow to a CAGR of ~25%.
    • Management also reaffirms its 2015 revenue guidance of ~$810M.
    • 2016 expectations include revenues of ~$870M and a 100-basis point expansion in operating profit margin versus 2015.
    | Dec. 10, 2015, 11:11 AM
  • Oct. 27, 2015, 4:11 PM
    • NuVasive (NASDAQ:NUVA): Q3 EPS of $0.35 beats by $0.08.
    • Revenue of $200.5M (+5.6% Y/Y) beats by $0.3M.
    • Shares +1.9%.
    | Oct. 27, 2015, 4:11 PM
  • Oct. 26, 2015, 5:35 PM
  • Oct. 9, 2015, 10:00 AM
    • Thermo Fisher Scientific (TMO +0.3%) initiated with Buy rating and $145 (15% upside) price target by Argus.
    • Fate Therapeutics (FATE +0.4%) initiated with Outperform rating and $8 (41% upside) price target by Raymond James.
    • Ocata Therapeutics (OCAT +2.1%) initiated with Outperform rating and $8 (66% upside) price target by Raymond James.
    • Eli Lilly (LLY +2.8%) upgraded to Outperform from Neutral by Credit Suisse. Price target raised to $105 (22% upside) from $89.
    • Abbott Laboratories (ABT +1%) upgraded to Overweight from Equal Weight by Barclays. Price target lowered to $52 (26% upside) from $55.
    • NuVasive (NUVA -1.6%) upgraded to Buy from Hold by Canaccord Genuity. Price target raised to $58 (16% upside) from $52.
    • Amicus Therapeutics (FOLD +5.4%) upgraded to Buy from Neutral with an $8 (11% upside) price target by Chardan Capital.
    • Bluebird bio (BLUE +1.5%) upgraded to Overweight from Equal Weight by Morgan Stanley. Price target maintained at $143 (61% upside).
    • Pfizer (PFE +0.5%) upgraded to Outperform from Equal Weight by Morgan Stanley. Price target raised to $38 (15% upside) from $35.
    • Vertex Pharmaceuticals (VRTX +1.2%) upgraded to Overweight from Equal Weight by Morgan Stanley. Price target raised to $148 (35% upside) from $118.
    • Alexion Pharmaceuticals (ALXN -0.2%) upgraded to Overweight from Equal Weight by Morgan Stanley. Price target raised to $211 (29% upside) from $186.
    | Oct. 9, 2015, 10:00 AM | 12 Comments
  • Jul. 29, 2015, 10:08 AM
    • NuVasive (NUVA +7.2%) Q2 results: Revenues: $202.9M (+6.4%); COGS: $48.4M (+8.0%); R&D Expense: $8.8M (-12.9%); SG&A: $115.3M (-1.5%); Net Income: $10.3M (+351.2%); EPS: $0.20 (+322.2%); Quick Assets: $278.7M (-23.2%); CF Ops: $35.2M (-27.1%).
    • 2015 Guidance: Revenue: $810M; GAAP EPS: $1.18 from $1.12; Non-GAAP EPS: $1.17 from 1.10.
    | Jul. 29, 2015, 10:08 AM
  • Jul. 28, 2015, 4:10 PM
    • NuVasive (NASDAQ:NUVA): Q2 EPS of $0.31 beats by $0.06.
    • Revenue of $202.9M (+6.4% Y/Y) beats by $2.19M.
    | Jul. 28, 2015, 4:10 PM
Company Description
NuVasive, Inc. is a medical device company, which is focused on the design, development, and market of surgical products to treat the spine. Its products include a minimally disruptive surgical platform called Maximum Access Surgery, in addition to biologics, cervical and motion preservation... More
Sector: Healthcare
Industry: Medical Instruments & Supplies
Country: United States